AJG:NYSE

Arthur J. Gallagher & Co.

Data as of 2026-03-10 - not real-time

$217.78

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Arthur J. Gallagher (AJG) is trading around $218, just below its 20‑day SMA of $218.5 and well under its 50‑day ($240) and 200‑day ($279) moving averages, signaling a bearish price environment. The RSI sits near 40, indicating limited upside momentum, while the MACD histogram is modestly positive but the overall trend remains bearish with decreasing volume. Valuation metrics are stretched – the trailing PE of ~38 is more than double the industry average of 17, and the DCF‑derived fair value of roughly $111 is far below the current price, suggesting the stock is overvalued on a fundamentals basis. Nonetheless, analyst consensus is bullish, with a mean target price of $282, implying a potential upside of about 29% from today’s level.
Fundamentally, AJG posted $13.0 B in revenue, growing 36.7% YoY, and maintains solid profitability with a gross margin of 42% and operating margin of 10%. The company generates strong cash flow ($1.93 B operating, $1.08 B free) and supports a 1.29% dividend yielding 45% payout, indicating dividend sustainability. Recent strategic moves, such as the acquisition of German broker Krose GmbH, expand its European footprint and bolster organic growth prospects. The balance sheet shows high debt ($13.6 B) but a low beta (~0.32) and modest ROE (~7%), positioning AJG as a relatively defensive player within the insurance brokerage sector.

Trading Recommendations

Short Term

< 1 year
sell
Conviction: 7/10

Key Factors

  • Price below key moving averages and support level
  • Bearish technical momentum (RSI, volume decline)
  • Current valuation far above intrinsic estimates

Medium Term

1–3 years
buy
Conviction: 8/10

Key Factors

  • Strong revenue growth and expanding international footprint
  • Attractive dividend yield with sustainable payout
  • Analyst consensus target price indicating ~30% upside

Long Term

> 3 years
buy
Conviction: 7/10

Key Factors

  • Durable business model with recurring brokerage fees
  • Continued acquisition strategy enhancing market share
  • Low beta and solid cash generation supporting dividend stability

Key Metrics & Analysis

Financial Health

Revenue Growth36.70%
Profit Margin11.48%
P/E Ratio37.9
ROE6.91%
ROA2.24%
Debt/Equity58.35
P/B Ratio2.4
Op. Cash Flow$1.9B
Free Cash Flow$1.1B
Industry P/E17.4

Technical Analysis

TrendBearish
RSI40.1
Support$195.00
Resistance$242.00
MA 20$218.49
MA 50$240.20
MA 200$278.93
MACDBullish
VolumeDecreasing
Fear & Greed Index75.89

Valuation

Fair Value$111.40
Target Price$281.94
Upside/Downside29.46%
GradeOvervalued
TypeGrowth
Dividend Yield1.29%

Risk Assessment

Beta0.32
Volatility43.69%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies. Not financial advice. Always do your own research before making any investment decisions.